Ma Jiaqi, Hou Leina, Liang Xiufen, Yan Bin, Dai Qiang, Wang Yunmei, Gao Hongbian, Zhu Jiang, Song Canxu, Yuan Quan
Department of Radiology, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China.
Department of Anesthesiology, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China.
Front Oncol. 2024 May 24;14:1325362. doi: 10.3389/fonc.2024.1325362. eCollection 2024.
Magnetic resonance imaging (MRI)-guided wire localization can be applied to assist to remove suspected breast lesions accurately. This study aimed to evaluate the clinical application value of this technique in Chinese women.
A total of 126 patients (131 lesions) who had underwent such technique in our hospital from April 2017 to June 2023 were enrolled. 1.5T MRI system and a wire localization device were used. Image characteristics, clinical features and postoperative pathology were collected and analyzed.
All of 126 patients (131 lesions) were successfully localized by MRI and excised for biopsy. There were 39 malignant lesions (29.77%) and 92 benign lesions (70.23%). There was no significant correlation between the morphology of DCE-MRI and the ratio of malignant lesions (P=0.763), while there was a statistical correlation between the BPE, TIC curve and the malignancy rate (P<0.05). All the lesions were assessed according to BI-RADS category of MRI (C4A=77, C4B=40, C4C=12, C5=2). The malignancy rates were as follows: 16.88% for 4A lesions (13/77), 37.50% for 4B lesions (15/40), 75.00% for 4C lesions (9/12) and 100% for 5 lesions (2/2). There was a significant correlation between the BI-RADS category and the incidence of benign-to-malignant lesions (P<0.001).
MRI-guided wire localization can assist to remove suspected breast lesions early, safely and accurately. This technique makes up for the deficiency of X-ray and ultrasound, improves the accuracy of diagnosis and resection therapy in intraductal carcinoma and early invasive carcinoma, and helps to improve the the prognosis of breast cancer.
磁共振成像(MRI)引导下的导丝定位可用于辅助准确切除疑似乳腺病变。本研究旨在评估该技术在中国女性中的临床应用价值。
纳入2017年4月至2023年6月在我院接受该技术治疗的126例患者(131个病变)。使用1.5T MRI系统和导丝定位装置。收集并分析图像特征、临床特征和术后病理。
126例患者(131个病变)均通过MRI成功定位并切除活检。其中恶性病变39例(29.77%),良性病变92例(70.23%)。动态对比增强磁共振成像(DCE-MRI)形态与恶性病变比例无显著相关性(P=0.763),而乳腺实质强化(BPE)、时间-强度曲线(TIC)与恶性率存在统计学相关性(P<0.05)。所有病变均根据MRI的乳腺影像报告和数据系统(BI-RADS)分类进行评估(C4A=77,C4B=40,C4C=12,C5=2)。恶性率如下:4A类病变为16.88%(13/77),4B类病变为37.50%(15/40),4C类病变为75.00%(9/12),5类病变为100%(2/2)。BI-RADS分类与良恶性病变发生率之间存在显著相关性(P<0.001)。
MRI引导下的导丝定位可辅助早期、安全、准确地切除疑似乳腺病变。该技术弥补了X线和超声的不足,提高了导管内癌和早期浸润癌的诊断及切除治疗的准确性,有助于改善乳腺癌的预后。